initi coverag outperform rate gritston
creat neoantigen vaccin treatment cancer ind activ lead candid
initi immunogen data expect
potenti mss-crc alon expect share appreci
success agent keytruda yescarta definit demonstr
cell capabl erad tumor yet mani patient fail benefit
therapi immunologist believ pauciti tumor specif cell one primari
caus patient fail respond checkpoint inhibit result
propos tumor specif neoantigen vaccin could provid readi pool tumor
specif cell lead deeper and/or numer respons
gritston core capabl expertis sequenc tumor biopsi order
determin mutat specif patient tumor proprietari
algorithm edg predict mutat capabl gener
immun respons gritston produc data indic process improv
neoantigen select nearli order magnitud select superior antigen
think gritston greatli increas odd success edg identifi patient
specif neoantigen well share neoantigen plan develop person
granit off-the-shelf product slate
select great antigen enough success vaccin must also effici recruit
train cell recogn select antigen gritston incorpor select
antigen heterolog prime boost vaccin protocol highli immunogen
differenti compani competitor initi immunogen data
granit could demonstr clinic
gritston granit slate product potenti util mani tumor type
think success product mss-crc could gener sale
respect hand support oper npv analysi mss-
indic share may under-valued opportun alon
pleas see page report import disclosur
believ gritston edg platform identifi superior neoantigen inclus
gritston vaccin anticip advantag accentu gritston
robust vaccin deliveri system therefor expect share outperform gritston
demonstr differenti gener signific neonatigen specif cell respons
ultim clinic benefit patient
initi phase trial
initi phase data
initi phase ii trial
granit gener sale
slate gener sale
slate demonstr efficaci outsid
sell access edg
granit fail demonstr efficaci
slate fail demonstr efficaci
gritston develop cancer vaccin compos tumor-specif neoantigen
treatment multipl tumor type gritston creat proprietari platform edg
identif cancer neoantigen believ order magnitud
accur publicli avail algorithm edg use genom transcriptom sequenc
data tumor biopsi predict surface-pres tumor-specif mutant peptid
target immun system furthermor gritston assembl
heterolog prime boost vaccin deliveri platform produc robust durabl
cell respons primat compani deploy platform develop person
granit off-the-shelf slate vaccin clinic trial granit expect
begin slate follow
checkpoint inhibitor immun therapi cell
proven cell capabl erad tumor howev rel
unspecif immun activ work fraction cancer patient gritston
other believ key reason approach fail patient cell
properli educ respond specif mutat neoantigen found within
patient tumor infecti diseas vaccin demonstr abil
educ cell recogn infecti agent uniqu featur ultim kill
pathogen if/when subject infect target pathogen gritston goal
bring power vaccin oncolog combin edg
platform neoantigen identif potent heterolog prime-boost base
vaccin strategi goal vaccin properli educ cell insid
design vaccin import compon select
antigen target infecti diseas space identif rang
possibl target rel simpl nearli everi protein express pathogen
uniqu pathogen cancer much difficult vast major
protein express cancer cell ident found within healthi cell
furthermor mani tumor-specif protein share
patient final everi patient capabl respond everi potenti tumor
target fact gritston data indic patient incap respond
critic target
consequ gritston foundat edg rest two core function in-hous
dna/rna sequenc expertis proprietari purpose-built algorithm select
valid neoantigen vaccin could succeed rel avail algorithm
asset result nearli order magnitud improv abil
select neoantigen immun system capabl respond
result rel competitor believ gritston capabl select superior
neoantigen think belief part valid bluebird bio decis licens
right develop engin cell product direct target identifi
gritston edg platform
gritston plan deploy edg support develop two relat product
opportun patient edg select uniqu neoantigen gritston
offer treatment entir person vaccin granit program granit
ind accept fda septemb gritston expect begin phase
trial initi data follow patient edg select
neoantigen share across patient gritston offer treatment off-the-
shelf product slate program ind slate expect
appropri neoantigen select patient immun system must
educ attack cell express neoantigen decad vaccin research
demonstr antigen deliveri system lead robust immun
respons consequ even edg function design select ideal
neoantigen poor vaccin strategi could limit efficaci therefor third key
element gritston heterolog prime-boost vaccin strategi
incorpor chimpanze adenoviru vector rna-contain lipid nanoparticl
educ cell infecti diseas vaccin use compon human well
non-human primat nhp experi conduct gritston indic approach
among robust vaccin strategi importantli nhp gritston
approach abl gener antigen-specif cell count in-lin exceed
effect engin cell therapi gilead yescarta consequ believ
combin edg heterolog prime-boost vaccin give gritston
gritston complet ipo septemb inclus net proce
manag estim cash suffici take gritston
sever mileston across pipelin includ initi data granit program
initi phase i/ii trial nsclc mss-crc muc gea
public edg platform
initi immunogen data phase i/ii
initi phase ii trial nsclc mss-crc pdac
initi proof-of-concept data phase ii
cowen compani
compani market cap estim pro-forma enterpris
valu gritston approach potenti applic broad swath
oncolog includ bladder colorect gastric lung cancer safeti
immunogen demonstr granit phase trial manag plan
open phase ii expans cohort sever tumor type metastat
adjuv set also accompani initi slate program
rapid market phase ii/iii trial colorect microsatellit stabl mss non-
small cell lung cancer model commerci launch slate follow
granit think success colorect could support sale
granit slate combin base upon npv analysi
estim plu cash worth repres upsid
cowen compani
financi year growth total free year growth valu termin valu net dilut share per fulli dilut valu calcul cowen
cowen compani
cowen compani
rate incom incom rate incom incom cowen
gritston develop cancer vaccin compos tumor-specif neoantigen
treatment multipl tumor type goal educ patient immun system
recogn mutant peptid present surfac cancer cell gritston
develop proprietari platform edg identif cancer neoantigen
believ order magnitud accur publicli avail
algorithm edg use genom transcriptom sequenc data tumor biopsi
predict surface-pres tumor-specif mutant peptid target
immun system furthermor gritston assembl vaccin deliveri
platforma form heterolog prime-boostthat preclin nhp model
produc robust durabl cell respons introduc antigen compani
current two candid develop lead candid
person immunotherapi compris prime dose chimpanze adenoviru
encod patient-specif antigen follow sever boost dose lipid-
encapsul self-amplifi rna encod antigen given
intramuscularli phase i/ii trial test combin
system nivolumab local ipilimumab treatment variou solid tumor
includ metastat non-smal cell lung cancer microsatellit stabl colorect
cancer ind trial submit august sinc accept
fda trial expect initi initi immunogen data
expect gritson follow-on product incorpor fix set
cancer neoantigen identifi edg share patient particular
tumor type off-the-shelf product expect address
patient common tumor type expect enter clinic
beyond develop vaccin august gritston engag
partnership bluebird bio identifi tumor-specif antigen cognat
tcr use bluebird cell therapi platform anticip share
outperform gritston immunotherapi progress clinic
order immun system recogn foreign invad cell throughout bodi
continu process protein produc peptid fragment
peptid present cell surfac surveil cell becom
infect viru instanc foreign viral protein express cytosol
process short peptid peptid load onto class protein
call major histocompat complex class mhc-i subsequ present
cell surfac within context mhc-i foreign peptid recogn
circul cytotox cell express appropri cell receptor tcr
vast repertoir cell express variou tcr potenti recogn
differ peptid constantli circul surveil bodi infect cell
prevent auto-react normal cell cell train earli
develop thymu cell gener tcr recogn self-peptid
elimin stage prevent self-recognit ensu autoimmun
foreign protein also creat outsid cell invad pathogen
protein engulf special cell immun system call antigen
present cell apc apc process foreign protein first hydrolyz
smaller peptid load onto mhc class ii mhc-ii molecul
molecul like mhc-i also present cell surfac recogn
helper cell express tcr recogn bound foreign peptid
bind mhc-ii molecul load foreign peptid helper cell
coordin immun respons foreign invad stimul antibody-
produc cell cytotox cell vaccin work activ direct immun
system particular target essenti simul occur actual
infect pathogen reason vaccin deliveri technolog best
approxim condit present actual infect tend produc
cancer mutat aberr gene express render cancer cell distinct
healthi tissu aris differ present opportun
immun system recogn cancer foreign mount attack
elimin malign cell success novel immune-oncolog agent
checkpoint inhibitor antibodi adopt cell therapi
cell til proven cell capabl recogn
chang gener durabl even cur respons howev patient
benefit therapi consult believ one explan tumor
specif epitop result tumor cellular alter may present
within proper context costimul microenviron etc allow
effici gener immun respons conceptu similar mani
infecti diseas pathogen evad recognit immun system vaccin
pathogen success abl present antigen
immun system within differ optim set occur activ
infect consult therefor believ possibl take
approach cancer epitop order develop therapeut vaccin either
induc clinic respons delay/prev relaps
known time immun system abl recogn infiltr
ultim kill tumor howev cancer patient often incap use
immun cell control clear tumor activ block
number inhibitori signal pathway necessari
cell specif either absent present low frequenc effect
much excit gener clinic success checkpoint inhibitor
ipilimumab yervoy pembrolizumab keytruda nivolumab opdivo
address first problem form therapi revolution
treatment certain form cancer therapeut benefit appear limit
patient heavili mutat tumor melanoma lung cancer pre-exist
infiltr cell inflam hot tumor
thought releas brake immun system cell enabl
attack cancer cell via recognit tumor-specif neoantigen tsna present
cancer cell surfac recent studi patient respond checkpoint inhibitor
therapi valid model critic paper synder et al nejm
rivzi et al scienc publish two scientif co-found gritston
demonstr respons ipilimumab antibodi pembrolizumab
antibodi correl presenc neoantigen identifi
tumor sequenc melanoma non-smal cell lung cancer nsclc patient
respect tsna-specif cell also identifi respond patient
found expand follow checkpoint inhibitor therapi unclear efficaci
driven de novo creation tsna-specif cell expans pre-exist
tsna-specif cell clone furthermor other found tsna-specif cell
found infiltr solid tumor call tumor infiltr lymphocyt til
cell expand ex vivo reintroduc patient order
treat cancer demonstr either simpl increas tsna-specif
cell expans without inhibitori signal tumor suffici induc
respons checkpoint inhibitor therapi deep durabl
respons observ minor treat cancer patient despit de-
repress immun cell tumor effect target patient
could due insuffici numer pool pre-exist tumor-specif cell
prime attack upon introduct checkpoint inhibit
failur immun system develop capac recogn cancer neoantigen
gritston hypothes induc robust cell respons tsna
express individu patient tumor efficaci checkpoint inhibitor therapi
extend much broader popul cancer patient target tsna
promis approach sever reason clinic evid suggest natur
target tsna cell underli much efficaci checkpoint inhibitor
therapi tcr specif tsna unlik elimin central
toler tsna present healthi tissu point develop
target tsna leav healthi tissu untouch tissu devoid
tsna minim toxic patient intact immun system tsna-
express tumor theoret amen tsna-target therapi
gritston goal
identifi tsna individu patient tumor analyz genom
transcriptom sequenc data tumor biopsi
use edg platform predict tsna like present
manufactur vaccin express top tsna edg analysi
deploy vaccin educ patient immun system mount respons
tumor
gritston believ approach address broad popul cancer patient
integr seamlessli current clinic practic importantli gritston believ
collect biopsi deliveri intramuscular vaccin minim side-
effect allow vaccin use commun oncolog set
cancer commonli aris eventu evolv state high rate damag
genom result mani mutat mutat sometim lead
product mutant protein protein includ mutant protein produc
within cell process variou machineri cell peptid fragment
present surfac cell mhc also call hla class molecul
potenti recognit cell small fraction mutat cancer
genom result neoantigen ultim present cell surfacegritston
estim
build effect tsna-target immunotherapi one must first determin
mani mutat present tumor lead neoantigen present cell
surfac recogn cell one gritston competitor
cancer vaccin space conduct studi demonstr
public avail algorithm determin neoantigen present mhc
compar empir neoantigen identif procedur atla public
avail algorithm netmhc solid tumor patient geneocea report
cell neoantigen predict netmhc confirm vivo atla
addit antigen atla identifi vivo cell respons
predict netmhc cell neoantigen atla confirm netmhc
predict neoantigen atla identifi neoantigen predict
netmhc gritston report studi public algorithm perform
reveal similar defici therefor gritston sought creat proprietari
first step identifi tsna immun system direct
obtain high qualiti dna/rna sequenc data order identifi rang
mutat present tumor could theoret present
immun system gritston believ dna rna sequenc commod
intern capabl obtain use high-qual sequenc data
core-needl tumor biopsi provid competit advantag
gritston plan use formalin-fix paraffin-embed ffpe core needl tumor
biopsi identifi neoantigen sinc form biopsi routin collect
molecular character tumor biopsi commonli perform order
guid choic cancer therapi therefor gritston anticip
platform fit seamlessli current clinic practic
unfortun difficult extract qualiti sequenc data ffpe sampl
partli due instabl rna sampl rna data particularli import
gritston provid inform mani mutat cancer
genom give rise express protein highli express mutant
protein addit broad transcriptom data may provid util
predict spectrum neoantigen express cell surfac exampl
under-express differ allel mhc gritston estim commerci
provid high rate sequenc failureonli exom
transcriptom success sequenc ffpe sampl contrast gritston
report hand sampl sequenc success
rather attempt salvag publicli avail algorithm gritston sought
deploy sequenc ai/machin learn expertis develop vastli superior
entir proprietari algorithm gritston name algorithm edgeepitop
discoveri cancer genom build edg algorithm gritston collect
fresh frozen tumor resect patient variou tumor type includ lung
colon ovarian gastric patient divers background order
broad coverag mhc/hla type sampl analyz next-gener
dna sequenc identifi tumor specif mutat follow next-gen
rna sequenc quantifi gene express ensur tumor specif mutat
activ express tumor final gritston perform mass
spectrometri identifi peptid fragment gener rna
present cell surfac hla molecul total one million hla-
present peptid captur data addit publish peptid
databas use train proprietari neoantigen predict model use machin
base pattern train dataset edg use featur dna/rna
sequenc data obtain tumor biopsi comput probabl given
mutat produc hla-pres peptid edg therefor use
identifi patient whose tumor predict good chanc respond
neoantigen vaccin priorit peptid inclus neoantigen vaccin
perform edg platform stress test abil
accur predict hla-pres peptid two method patient sampl
analyz mass spectrometri held-out train edg dna
rna sequenc data sampl use edg predict
mutant peptid like present hla posit predict valu
ppv edg test case number edge-predict antigen
actual detect cell surfac mass spectrometri
fold improv ppv gener public avail algorithm
patient sampl level improv nearli order magnitud give
gritston much better chanc correctli identifi action neoantigen target
inclus vaccin manag report algorithm improv
rais ppv edg
edg superior identif hla-pres peptid
gritston also test edg abil identifi tumor-specif neoantigen
target cell patient dataset cell-target neoantigen
compil four publish studi togeth analyz mutat
patient twelv patient detect neoantigen-target cell
total neoantigen identifi analyz dna rna sequenc data
patient select top neoantigen edg abl identifi least one
cell-target neoantigen patient wherea public avail
algorithm identifi cell-target neoantigen patient furthermor
edg use identifi top neoantigen number antigen
plan inclus gritston vaccin total verifi t-cell
target neoantigen identifi
gritston continu improv edg platform use data observ
clinic studi identifi tsna-target cell nsclc patient receiv checkpoint
inhibitor therapi patient analyz thu far edg abl success identifi
cell-target neoantigen patient note howev
absenc detect cell respons edge-predict neoantigen
necessarili impli neoantigen target possibl patient
possess tcr specif neoantigen cell contain tcr simpli
infrequ detect peripher blood importantli edg continu
updat data gritston clinic trial becom avail reveal
addit inform pattern mutat lead present
neoantigen type neoantigen immun respons
success stimul
edg initi train base upon data peptid present hla class
classic recogn cytotox cell class hla gritston
primari focu work continu expand applic edg patient
divers background harbor rarer class hla type gritston also initi
program train edg predict peptid present hla class ii
classic recogn helper cell
success identifi tumor-specif neoantigen next step build
effect target immunotherapi direct immun system kill cell express
neoantigen could theoret achiev either directli introduc
cell specif neoantigen engin cell therapi educ
vaccin immun system recogn neoantigen gritston plan
use latter cancer vaccin approach order gener cell target top
like tsna identifi edg
prior attempt cancer vaccin develop met limit success like due
larg part failur induc suffici strong immun respons drive
effect attack tumor cell could due need break immun
toler vaccin self-antigen use inferior vaccin platform
nake peptid incomplet engag immun system singl vector
and/or gener respons vaccin vector rather intend
cancer antigen upon repeat dose gritston plan overcom issu
use neoantigen identifi edg heterolog prime-boost scheme
strategi shown promis non-human primat nhp model use
gritston lead product candid
gritston person immunotherapi compris initi prime dose
one vector follow sever boost dose differ vector prime
vector chimpanze adenoviru chadv engin express pre-select
neoantigen chadv provid opportun present self-neoantigen foreign
context therefor drive robust immun respons essenti act
adjuv chadv histori safeti efficaci infecti diseas vaccinolog
drive gener robust cell respons importantli chadv vector
highli immunogen continu dose could result immun system
focus chadv antigen rather desir neoantigen consequ booster
vaccin must perform differ vector
gritston booster compris self-amplifi mrna sam encod
neoantigen encapsul lipid nanoparticl lnp cell take samrna
follow inject booster dose rna begin replic replic
effect gener larg amount neoantigen double-strand rna
intermedi creat rna replic also recogn foreign toll-lik
receptor therebi help recruit cell site neoantigen express
vector switch chadv samrna avoid issu blunt immun
respons boost inject due immun recognit initi vector
order evalu effect heterolog prime-boost strategi
elicit cell respons neoantigen gritston perform preclin studi
nhp consult report vaccin studi conduct nhp gener
predict cell respons ultim observ human fold
reduct cell respons typic observ human compar nhp
gritston studi chadv samrna vector manufactur express non-self-
antigen administ nhp blood sampl collect time
assess cell respons administ antigen cell respons
observ shortli administr chadv effect elev
follow dose samrna booster
addit co-administr antibodi improv initi cell
respons elev cell respons enhanc subsequ
dose booster follow two dose booster anim
antigen-specif cell made total circul cell anim
even account project fold reduct respons
system translat human level respons impress level
durat cell respons gritston immunotherapi seen nhp compar
seen patient respond adopt cell therapi clinic trial
therefor edg identifi neonantigen capabl drive tumor erad
gritston vaccin approach appear capabl deliv cell provid
clinic respons term safeti flu-lik symptom temporari elev
cytokin observ anim although manag report signific
safeti issu observ
importantli gritston first use chimpanze adenoviru human
exampl gsk conduct phase trial chadv base hcv vaccin candid
publish result scienc translat medicin common
inject site pain fatigu headach seriou advers event
report gsk also conduct trial chadv base rsv vaccin data
phase trial agent present eccmid one patient
low-dos cohort develop basal cell carcinoma one patient placebo
arm append otherwis seriou advers event
therefor believ gritston use chadv vector unlik gener
chadv prime vector manufactur in-hous gritston
biomanufactur facil pleasonton ca manufactur process lnp-
encapsul samrna simpler chadv therefor manag view
control process less core gritston success boost vector
initi manufactur octob gritston arbutu enter
collabor licens agreement use arbutuss lnp technolog
combin gritston neoantigen-encod samrna gritston paid arbutu
up-front agre pay develop mileston
commerci mileston low single-digit royalti net product sale
gritston estim initi entir process biopsi receipt shipment
vaccin take approxim week partli due steril test
adventiti agent chadv prepar requir fda
gritston anticip manufactur timelin eventu shorten
use improv releas assay nonetheless manag believ current
timelin accept treatment mani solid tumor patient due
gener slower progress tumor rel liquid tumor cell therapi
manufactur speed also view less import adjuv set
gritston focus target patient like deriv benefit
therapi exclud patient insuffici neoantigen pediatr
tumor low grade glioma patient high neoantigen burden
robust cell infiltr alreadi well serv checkpoint inhibitor therapi
trial enrol patient newly-diagnos metastat nsclc
gastroesophag cancer urotheli cancer relaps microsatellit stabl mss
phase i/ii trial enrol patient tumor type
receiv chemotherapi manufactur administ either
mainten therapi second-lin therapi phase portion
divid two part part patient given chadv prime follow
multipl dose level samrna sinc samrna previous test
human part patient also given iv opdivo accord label effort
boost immun respons gener immun monitor
patient perform collect patient blood tumor biopsi sampl
assess presenc abund neoantigen-specif cell blood
qualiti polyfunction cytotox potenti etc neoantigen-specif cell
infiltr neoantigen-specif cell tumor tumor shrinkag
determin ct scan
optim dose level samrna identifi part dose
taken part part addit heterolog prime-boost opdivo
patient also given subcutan yervoy dose vaccin local
inject yervoy done order maxim local concentr
drain lymph node cell educ take place also tri minim
system toxic known occur upon coadministr opdivo
yervoy juli gritston bristol-my enter clinic trial
collabor wherebi bristol suppli checkpoint inhibitor opdivo nivolumab
yervoy ipilimumab use trial
phase ii portion enrol single-arm expans cohort tumor
expect respons checkpoint inhibitor monotherapi mss-crc trial
may also enrol random cohort tumor known respons
checkpoint inhibitor therapi expans cohort may also includ use granite-
consolid therapi follow chemotherapi patient unresect
tumor use adjuv set prevent recurr
tumor high risk relaps post-resect adjuv set particular
gritston plan use cell free circul dna surrog biomark
effect prevent relaps ind
accept fda trial expect initi trial expect
enrol total patient accord clinicaltri gov initi immunogen data
trial expect
could support global sale mss-crc alon
american cancer societi estim approxim new
case major patient
microsatellit stabl mss approxim present metastat stage
iv diseas project incid continu declin rate
per year due partli earli screen detect diseas physician
consult estim first-lin patient elig second-lin
therapi anoth second-lin patient might go receiv third-lin
regimen gritston treat patient unless edg capabl
select antigen list total present probabl least one present
peptid model patient meet criterion altogeth result
elig mss-crc patient project
could launch declin patient assum similar incid
eu project achiev penetr popul
 penetr eu assum
launch somewhat price discount adopt cell immunotherapi
 eu price increas thereaft
therefor anticip could support sale
eu world-wide sale mss-crc alon
mutat gene kra egfr commonli found certain
tumor often underli hyperprolif capac surviv advantag
cancer cell so-cal driver mutat potenti gener
neoantigen peptid eventu present cancer cell surfac
therefor avail recognit immun system nci studi neoantigen-
specif tumor infiltr lymphocyt til patient identifi share kra
share neoantigen
marketnumb new case microsatellit stabl mss- elig neoantigen vaccin elig penetr patient receiv revenu per cours therapi sale marketnumb new case microsatellit stabl mss- elig neoantigen vaccin elig penetr patient receiv averag revenu per cours therapi sale eu sale cowen
gritston believ edg platform capabl identifi peptid
like present importantli share across sizabl patient popul
result gritston plan also develop pre-construct off-the-shelf vaccin slate-
direct share neoantigen construct
way compos twenti neoantigen cassett administ
chadv prime follow samrna boost twenti neoantigen includ
cassett howev share neoantigen common patient particular tumor
type rather patient-specif neoantigen
gritston carri analys use edg identifi common cancer mutat
variou tumor type like present patient differ hla type
analys gritston estim one share neoantigen like
share patient particular tumor type howev combin
share neoantigen total fraction patient harbor tumor present
least one preassembl neoantigen actual much higher fact gritston
estim patient common solid tumor like lung colorect
cancer may elig
expect come seri product design specif tumor type
version contain fix cassett share neoantigen
common particular tumor-typ neoantigen pre-select
therefor possibl manufactur vaccin advanc patient enter gritston
sequencing/edg process manag envis patient flow biopsi sampl
sequenc data enter edg edg predict patient
present share neoantigen patient refer off-
the-shelf treatment instead edg predict present uniqu neoantigen
patient refer program person vaccin
util prime-boost strategi therefor
differ patient patient bs
result gritston anticip may abl move
directli phase ii/iii clinic develop success
complet phase trial gritston plan test
combin checkpoint inhibitor initi tumor type evalu includ mss-
nsclc pancreat ductal adenocarcinoma ind expect
submit clinic develop begin shortli thereaft
proof-of-concept data could becom avail
could support global sale mss-crc
model mcrc patient project launch
declin patient assum similar incid
eu project mss-crc patient suffici expect neoantigen
elig receiv project penetr
patient patient eu given simplifi
manufactur assum would price slight discount granite-
model launch price eu
price increas thereaft given assumpt believ success
could support global sale
marketnumb new case microsatellit stabl mss- elig share antigen vaccin elig penetr patient receiv revenu per cours therapi sale marketnumb new case microsatellit stabl mss- elig share antigen vaccin elig penetr patient receiv averag revenu per cours therapi sale eu sale cowen
addit discoveri patient-specif share neoantigen use
edg platform gritston identifi number novel share tumor-specif
antigen mani cancer testi antigen cta class express
antigen restrict tumor immun privileg site testi
therefor theoret safe target immun system howev
antigen mutat process central toler may elimin
tcr specif antigen vaccin may valid approach
altern vaccin forc cell recogn antigen either
introduct synthet cars/tcr adopt cell therapi use
cell-engag bispecif interestingli gritston work train edg algorithm
involv identifi cell clone specif present peptid gritston
current plan diversifi clinic pipelin beyond vaccin cell
therapy/t cell engag therefor look monet find edg
gritston report initi work third-parti cro develop tcr-
mimet antibodi recogn shard tumor-specif antigen plan
eventu partner anoth compani develop antibodi incorpor
bispecif car-t platform gritston also intern capac identifi
natur tcr recogn antigen screen cell healthi hla-
august gritston enter collabor bluebird bio
gritston use edg platform identifi tumor-specif antigen provid
natur tcr bind antigen incorpor bluebird cell therapi
program term agreement gritston provid tcr bluebird
identifi valid antigen bluebird respons cost
associ develop manufactur commerci product
result collabor gritston receiv up-front addit
seri prefer stock invest gritston elig receiv
mileston associ certain develop regulatori commerci
mileston also receiv tier single-digit royalti sale bluebird
product util gritston natur tcr
gritston alon belief modern sequenc technolog allow
person neoantigen vaccin develop sever public privat compani
includ genocea person
vaccin earli clinic preclin develop competitor develop
variou algorithm predict tsna present major
mere modif public avail tool netmhc mhcflurri
aduro develop person ladd pladd platform combin innat
immun stimul activ listeria neoantigen vector contain patient-
specif tumor antigen express individu patient tumor cell
gener pladd vaccin cell obtain biopsi patient tumor
sequenc neoantigen identifi use aduro proprietari bioinformat
algorithm pladd strain creat integr vector carri
neoantigen sequenc listeria genom aduro initi phase trial
line microsatellit stabl mss colorect cancer patient data one patient treat
trial present european neoantigen summit april
present indic neoantigen specif cell respons detect
day ex vivo expans addit immunogen data expect
follow anticip complet initi proof concept phase trial
aduro plan initi trial combin pladd approach
antibodi mss colorect cancer
privat german compani develop cancer vaccin strategi
fixvac fix combin taa ivac-warehous person mixtur taa
ivac-mutanom neoantigen platform biontech ivac vaccin patient
sampl sequenc identifi tumor specif mutat mutat
enter proprietari algorithm select neoantigen believ like
present recogn patient and/or cell rna encod
neoantigen synthes incorpor liposom inject
patient inguin lymph node use ultrasound guidanc phase data stage
iv melanoma patient publish natur juli trial
neoantigen select patient enrol patient receiv dose within
day addit dose investig discret dose
consist liposom contain synthet rna encod distinct
peptid correspond select neoantigen total mutat
repres across patient follow vaccin immun respons
observ antigen administ de novo
respons among patient activ metastat diseas time vaccin
administr achiev cr achiev pr orr cr patient
previous fail yervoy remain cr month relaps
patient tumor found lost express therefor
immun cell recognit via class mhc present third metastat
patient progress follow vaccin achiev cr subsequ
pembrolizumab unclear extent vaccin may contribut
respons high risk patient began vaccin evid
diseas remain tumor-fre month addit phase trial test ivac-
warehous /- ivac-mutanom tnbc patient began enrol patient
septemb accord clinicaltri gov data expect march
neon clinic stage person cancer vaccin compani neon
conduct whole exom sequenc identifi tumor specif mutat proprietari
algorithm base upon netmhc version use select neoantigen
like bind patient hla-a hla-b protein class mhc molecul
select neoantigen per patient synthes long peptid
amino acid long peptid combin hiltonol form dose neo-
patient receiv prime dose within week follow boost week
phase trial result stage iiib/c stage iv melanoma publish
natur juli public report patient elig
surgic resect cur intent among enrol patient found
high mutat rate long peptid synthes
vaccin initi patient stage stage iv median time
week post-surgeri patient complet vaccin seri cell
respons detect direct ex vivo ifn- elispot although respons
detect peptid cell pre-stimul singl round
vitro expans prior neoantigen elispot test cell respons
peptid gener directli detect respons detect
vitro expans stage patient remain recurr free median follow-up
month stage iv patient evid recurr restag
perform end vaccin administ pembrolizumab
achiev on-going partnership bm neon initi phase
trial combin nivolumab patient unresectable/
metastat bladder cancer melanoma nsclc trial complet enrol
patient data expect interim data updat
expect esmo partnership merck neon initi phase trial
pembrolizumab chemotherapi nsclc patient may
genocea employ methodolog call atla antigen lead acquisit system
empir identifi cell antigen individu patient genocea identifi tumor
mutat whole exom sequenc build plasmid librari contain
mutat use librari atla identifi neoantigen epitop
present patient immun system recogn patient cell
specif librari put high-throughput screen protocol wherebi
mutant protein librari incub patient antigen present cell apc
cell mimick occur bodi patient apc take mutant
protein process epitop present epitop patient
cell patient cell recogn mutant protein mount respons
includ secret cytokin ifn- cell cultur media genocea
harvest media test presenc cytokin interest use
elisa multiplex array etc genocea initi phase i/ii trial person
cancer vaccin base atla platform trial enrol cancer
patient achiev evid diseas high risk relaps initi
immunogen data patient anticip
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
unprofit approv product like need rais
addit capit public market prior turn profit gritston pipelin
yet gener proof concept therefor compani face number clinic
regulatori commerci hurdl prior becom success make invest
recommend earli stage pre-commerci biotechnolog compani base upon
assess technolog probabl pipelin success potenti market
opportun event success howev compani lack tradit
financi metric believ good methodolog assign
specif target price stock
